Trial Profile
Intravesical Administration of Durvalumab (MEDI4736) to Patients With High-risk, Non-muscle-invasive Bladder Cancer (NMIBC). A Phase II Study With Correlative
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
- 04 Mar 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified March 2022).
- 22 Mar 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 22 Mar 2022 Planned primary completion date changed from 31 Aug 2021 to 31 May 2022.